MediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer’s Disease and Dementia

Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo. The LiBBY study evaluated MediPharm Labs’ proprietary oral cannabinoid formulation, developed and supplied exclusively by MediPharm Labs for use in the trial. TORONTO, July 14, 2026 (GLOBE NEWSWIRE) — MediPharm Labs […]